Advanced Genomic Engineering for Robust Microbial Cell Factories. Escherichia coli remains the most versatile host for synthetic biology and biomanufacturing. CD Biosynsis provides professional Gene Knock-in Services, leveraging advanced Lambda Red Recombineering, KIKO (Knock-in/Knock-out), and Dual-In/Out strategies to achieve seamless, markerless integration of single genes or entire metabolic pathways. Our platform is designed to build plasmid-less, marker-less recombinant strains with unparalleled genetic stability for industrial-scale production.
Get a Technical QuoteOur platform specializes in the precise insertion of heterologous DNA into pre-defined "neutral loci," ensuring genetic stability without compromising host fitness. We support the integration of complex logic circuits and ultra-long metabolic pathways.
| Service Tier | Technical Strategy | Best For | Standard Deliverables |
|---|---|---|---|
| Standard Knock-in | Lambda Red Recombineering | Single gene or small reporter insertion | 2 Validated stocks + Sanger Report |
| Large Fragment Integration | KIKO Vector System | Large DNA sequences (>5 kb) & whole pathways | Integrated strain + Genetic stability data |
| Iterative Engineering | Dual-In/Out Strategy | Step-by-step construction of complex genomes | Plasmid-less, marker-less recombinant strains |
| Precision Markerless Editing | FRT/FLP or sacB System | Complete removal of selection markers and replicons | Marker-free strain + WGS |
1. Rational Design
2. Fragment Construction
3. Genomic Integration
4. Validation & Delivery
Evaluation of neutral integration sites and codon optimization of exogenous sequences.
Formal project proposal and Mutual NDA signing.
Assembly of KIKO integration vectors or linear fragments with high-homology arms.
Synthesis of custom regulatory elements and reporters.
Lambda Red-mediated recombination or plasmid-based integration/resolution.
Precise removal of markers using site-specific recombinases or counter-selection.
Validation via Junction PCR and full-length Sanger sequencing of the insert.
Final QC report delivery (Optional NGS/WGS).
To provide the highest level of service, our team continuously benchmarks our internal protocols against landmark studies in the field of E. coli genome modification.
Addressing the size limitations of traditional integration, we utilize the KIKO vector architecture. This technology allows for the rapid integration of large DNA sequences, including whole metabolic pathways, onto characterized chromosomal loci, significantly reducing engineering timelines.
(Reference: Sabri et al., Microbial Cell Factories)
Using the Dual-In/Out strategy, we construct recombinant strains without the need for maintaining plasmids. This iterative method allows for the precise building of complex genotypes through sequential rounds of integration and resolution while maintaining a marker-less final state.
(Reference: Minaeva et al., BMC Biotechnology)
For industrial compliance, the removal of antibiotic markers and replicons is critical. We utilize high-efficiency systems to ensure that heterologous DNA is integrated into the E. coli chromosome with the total removal of auxiliary sequences used during construction.
(Reference: Martinez-Morales et al., Journal of Bacteriology)
1. How do you select the integration site?
We target well-characterized "neutral sites" that allow for high expression levels without interfering with the host's primary metabolic functions.
2. Can you integrate multiple pathways at different locations?
Yes. Through iterative rounds of Dual-In/Out or sequential recombineering, we can stack multiple pathways across the genome.
3. What is the maximum size of DNA you can knock in?
While traditional methods struggle above 3 kb, our KIKO-based systems and iterative strategies can handle fragments exceeding 10 kb.
4. Why choose chromosomal integration over plasmid expression?
Integration eliminates plasmid loss, reduces metabolic burden, and removes the need for antibiotics in large-scale fermenters.
5. How do you verify the accuracy of the integrated sequence?
We perform Junction PCR to confirm the site and use long-read sequencing or NGS to ensure the entire insert is 100% accurate.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.